In addition, stockholders voted to defeat stockholder proposals regarding: disclosing the company’s animal welfare policy; preparing a report on limiting the supply of prescription drugs in Canada, and providing additional disclosure of political contributions.
Another stockholder proposal – to seek recoupment of incentive bonuses from Wyeth management when business performance targets were reasonably determined not to have been achieved – was passed.
Highlighting the company’s performance over the year, chairman and CEO Robert Essner said: “Our strong performance reflected the convergence of several factors, including solidifying our position as a leading biotech company and realizing the success of our primary care sales force model.”